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Background: High-dose short-term methylprednisolone is the recommended treatment in the management of
multiple sclerosis relapses, although it has been suggested that lower doses may be equally effective. Also,
glucocorticoids are associated with multiple and often dose-dependent adverse effects. This quantitative
benefit-risk assessment compares high- and low-dose methylprednisolone (at least 2000 mg and less than
1000 mg, respectively, during at most 31 days) and a no treatment alternative, with the aim of determining
which regimen, if any, is preferable in multiple sclerosis relapses.
Methods: An overall framework of probabilistic decision analysis was applied, combining data from different
sources. Effectiveness as well as risk of non-serious adverse effects were estimated from published clinical
trials. However, as these trials recorded very few serious adverse effects, risk intervals for the latter were
derived from individual case reports together with a range of plausible distributions. Probabilistic modelling
driven by logically implied or clinically well motivated qualitative relations was used to derive utility
distributions.
Results: Low-dose methylprednisolone was not a supported option in this assessment; there was, however,
only limited data available for this treatment alternative. High-dose methylprednisolone and the no treatment
alternative interchanged as most preferred, contingent on the risk distributions applied for serious adverse
effects, the assumed level of risk aversiveness in the patient population, and the relapse severity.
Conclusions: The data presently available do not support a change of current treatment recommendations.
There are strong incentives for further clinical research to reduce the uncertainty surrounding the
effectiveness and the risks associated with methylprednisolone in multiple sclerosis relapses; this would enable
better informed and more precise treatment recommendations in the future.
Keywords: Glucocorticoids, Corticosteroids, MS, Neurology, Neuropathy, Demyelinating diseases,
Pharmacoepidemiology, Pharmacovigilance, Clinical epidemiology, Decision analysisBackground
Glucocorticoids are the only pharmacological interven-
tion with a demonstrated effect on multiple sclerosis
(MS) relapses, with high-dose short-term methylprednis-
olone being the currently recommended first line treat-
ment [1]. Nevertheless, the optimal methylprednisolone
treatment regimen is unknown [1], and meta-analysis
has even suggested that low-dose methylprednisolone
may be as efficacious as the high-dose regimen [2]. A
whole array of different adverse effects is attributed to* Correspondence: ola.caster@who-umc.org
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(http://creativecommons.org/publicdomain/zeglucocorticoids, many of which are dependent on dose
and duration of treatment [3, 4]. Recently, high-dose
methylprednisolone was associated with hepatotoxicity
[5, 6], a previously unrecognised risk that may also
warrant consideration. Hence, there is a clear need for
a systematic joint evaluation of the beneficial and ad-
verse effects of methylprednisolone in the management
of MS relapses, to challenge treatment recommenda-
tions, support clinical decision making and inform
future research [7]. Specifically, neurologists and MS
patients would be well served by a comparison between
low- and high-dose methylprednisolone, to maximiseis article is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Caster and Edwards BMC Neurology  (2015) 15:206 Page 2 of 23chances of treatment benefit while avoiding unneces-
sary risk of adverse effects.
There are several systematic reviews that investigate
the use of methylprednisolone and other glucocorticoids
in MS relapse management [1, 2, 8–10]. Although there
is a paucity of data from formal studies, some of these
reviews contain quantitative analyses with respect to ef-
fectiveness. However, experiences of adverse effects are
typically presented separately, and to the best of our
knowledge there exists no previous evaluation that con-
siders the likelihood and desirability of relevant benefi-
cial and adverse effects jointly.
A number of methods have been proposed for formal
benefit-risk assessment [11–13], most of which focus on
regulatory decisions regarding initial market approval.
However, current regulatory guidelines put clear em-
phasis also on the benefit-risk balance in the post-
marketing setting, and formal assessments are required
in the face of significant new risks [14]. We have previ-
ously devised a methodology for modelling the utility of
drug effects that is appropriate to the post-marketing
setting, as it does not require timely and costly elicit-
ation studies [15]. It also avoids the questionable as-
sumptions inherent to methods based on aggregating
health state utility over time, e.g. using quality-adjusted
life years [15].
The primary aim of this study is to provide a quantita-
tive benefit-risk assessment of methylprednisolone in
MS relapse management, to determine whether treat-
ment is to be recommended, and, if so, whether high or
low dose is preferable. Our main finding in this respect
is that low-dose methylprednisolone is an inferior alter-
native both to high-dose methylprednisolone and to the
no treatment choice, based on available data. The sec-
ondary aim is to demonstrate how various methods can
be combined through probabilistic decision analysis to
yield a transparent and rigorous framework for post-
marketing benefit-risk assessment that can accommo-
date relevant information from disparate sources.
Methods
Overview
Drug benefit-risk assessment is here approached as the
analysis of a treatment decision problem for a hypothet-
ical representative of the relevant patient population.
The same framework could be used for a real patient by
incorporating his or her specific preferences.
The flow of the evaluation largely follows that of cus-
tomary decision analysis [16]: the decision problem, its
objective and its alternatives are defined; the relevant
effects are identified and modelled in a tree to form clin-
ical outcomes; probability and utility variables are esti-
mated; and each alternative is evaluated with respect to
expected utility as a basis for comparison. Expectedutility is an overall measure of how preferable an alter-
native appears.
In addition, the evaluation adopts probabilistic sensi-
tivity analysis [17], meaning that each probability and
utility variable is specified as a distribution and sampled,
resulting in distributions of the alternatives’ respective
expected utilities. The primary evaluation metric is the
preference rate, which measures the fraction of sampling
iterations in which a given alternative has the highest
expected utility [15]. The preference rate of an alterna-
tive therefore estimates the probability of that alternative
being the preferred one, given the specified model.
This framework is illustrated in Fig. 1, including an
explanation of how expected utility is calculated.
Definition of the decision problem
This assessment analyses a treatment decision of a puta-
tive MS patient in acute relapse, with the objective of
maximising health during the course of the relapse.
Three alternatives are considered: high-dose methyl-
prednisolone, low-dose methylprednisolone and the no
treatment choice. High dose was defined as at least
2000 mg methylprednisolone cumulatively during at
most 31 days, and low dose was defined as less than
1000 mg cumulatively during the same period of time.
The time horizon of the assessment is the duration of a
single relapse, which was taken to be 6 months [18].
Optic neuritis is here considered a different indication
than MS relapses and hence excluded from the assess-
ment. No differentiation is made with respect to the
route of administration.
Selection of beneficial and adverse effects
The most common clinical endpoint in controlled trials of
MS relapses is an improvement of at least one point on
the expanded disability status scale (EDSS) [19]. Hence
this degree of improvement was adopted as our definition
of benefit. It was labelled a ‘reduced relapse’, in contrast to
a ‘standard relapse’ where there is less or no improvement.
Serious and non-serious adverse effects were handled
differently in the analysis. The latter were considered
jointly as a group, because their main significance from
a benefit-risk perspective is likely to be their aggregated
burden as a nuisance to patients.
Serious adverse effects were defined as being manifested
by either life-threatening or persistently disabling reactions.
These effects were selected from VigiBase®, the WHO inter-
national database of suspected adverse drug reactions [20],
since this data source reflects actual concerns about drug
treatment in clinical practice and captures rare events un-
likely to be seen in small clinical trials. All reports in Vigi-
Base as of May 2012 listing methylprednisolone were
extracted, and those reports where treatment could be clas-
sified as high- or low-dose were retained as two groups.
Fig. 1 (See legend on next page.)
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Fig. 1 Overview of the applied drug benefit-risk assessment framework. 1st panel: It is identified what decision problem is considered; what the
alternatives are; and which effects should be included. 2nd panel: A decision tree model is constructed. 3rd panel: For each clinical outcome, i.e.
branch in the tree, distributions are specified for probability and utility variables. These are denoted by p and u, respectively. Here, one of the
clinical outcomes from high-dose methylprednisolone (reduced relapse – psychosis – second unspecified consequence of psychosis) is used for
illustration. Superscripts denote alternatives; subscripts denote paths as the tree branches. For each iteration of the probabilistic analysis, values
are sampled for all variables, and expected utilities (denoted E) are computed for all alternatives, as seen in the 4th panel. The expected utility is
the probability-weighted sum of utilities over all clinical outcomes, as indicated in the equations. In this example, the same 14 clinical outcomes
are considered for all alternatives. 5th panel: Finally, the preference rate of each alternative is computed. Note that the entire scheme or selected
parts thereof could be subjected to (non-probabilistic) sensitivity analysis
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A frequency listing was constructed of reported MedDRA
Preferred Terms and High-Level Terms, for the two groups
separately. A clinical reviewer (IRE) went through the lists
separately, and each encountered term that was considered
potentially life-threatening or persistently disabling, and
reasonably likely to be due to treatment, was mapped to a
preliminary term grouping. The top ten adverse effects thus
constructed for each dose group were then taken further
and rigorously defined as groups of MedDRA Preferred
Terms. During the review, the actual frequencies of the
various reported terms were hidden.
For each included adverse effect, three different ser-
ious outcomes were considered: death, persistent disabil-
ity and life-threatening though non-lethal reactions.
While a lethal outcome is relatively straightforward to
capture, the other two outcomes were identified either
intrinsically by the nature of the reported term, or based
on explicit information on the reports. (For complete
definitions, see Additional file 2). Within a given report,
the outcome classification of an adverse effect was hier-
archical in the order listed above. This means that, for
example, if two reactions on the same report suggested
hepatotoxicity, of which one reaction was persistently
disabling and the other life-threatening, the report
would be counted only towards the persistent disability
outcome. However, different reactions signifying separ-
ate adverse effects on the same report were counted sep-
arately and were therefore not necessarily coupled with
the same outcomes. Only adverse effect-outcome combi-
nations reported at least three times for both groups
together were further considered.
Modelling of beneficial and adverse effects
All considered effects were modelled together in a tree
structure. The small illustrative decision tree in the
second panel of Fig. 1 can be used to view the general
modelling strategy. The top level corresponds to the
three alternatives, each of which is followed by the same
sub-tree. This sub-tree, in turn, contains three levels,
where the first corresponds to the beneficial effect. The
second level contains the serious adverse effects, as-
sumed for simplicity to be mutually exclusive on account
of their rarity. Finally, the third level either correspondsto the outcome of the serious effect from the second
level (psychosis or hepatotoxicity in the figure); or, in
case of no serious adverse effect, the third level delin-
eates two possible events: no adverse effect at all, or at
least one non-serious adverse effect. Each branch thus
constructed forms one possible clinical outcome.
Estimation of probability variables
As illustrated in the third panel of Fig. 1, each clinical
outcome entails a series of events that each has an asso-
ciated probability variable with a distribution. In the ex-
ample used in Fig. 1, these events are in turn reduced
relapse, psychosis and some unspecified serious outcome
of psychosis. In general, estimation of three types of
probability variables is required for each treatment alter-
native: the effectiveness, i.e. the probability of a reduced
relapse; the risk of any non-serious adverse effect; and
the respective risks of the included serious adverse
effect-outcome combinations.
Effectiveness
Data to estimate the effectiveness of the various alter-
natives was taken from published clinical trials. All
papers included in, cited by, or citing any of the
available systematic reviews on methylprednisolone in
MS were considered [1, 2, 8–10, 21, 22]. Study arms
where patients were given either high- or low-dose
methylprednisolone as defined above or placebo for at
most 31 days were included from trials fulfilling the
following criteria:
 Included patients were in acute relapse and
diagnosed with either relapsing-remitting or
progressive MS.
 The trial was randomised and treatment was blinded
to both patients and clinical assessors.
 Patients were assessed clinically, with results
reported as the fraction of patients with an
improvement of at least one EDSS point compared
to start of treatment, or an equivalent thereof.
If several EDSS assessments were made in a single
trial, the latest within the interval between 14 and
28 days from start of treatment was used.
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sidered alternatives were then estimated by combing the
fractions of improved patients reported in the various
identified studies, using the hierarchical beta-binomial
model with a non-informative prior distribution [23].
Sampling from the posterior distributions relied on
Markov chain Monte Carlo (MCMC) simulation with
the Metropolis-Hastings algorithm [24, 25]. (For details,
see Additional file 3).
Risk of any non-serious adverse effect
Data to estimate the risk of one or more occurrences of
non-serious adverse effects were also taken from pub-
lished clinical trials. The same basic search strategy as
described for the effectiveness data was used, but treat-
ment arms were included on other criteria, namely:
 The trial was prospective, but not necessarily
randomised or blinded.
 Adverse events were reported in such a way that the
number of affected patients could be inferred.
Risk distributions were estimated in the same way as
for effectiveness, with the exception of low-dose methyl-
prednisolone. The reason was insufficient data: only two
trials were identified [26, 27], each with only ten patients
on low-dose methylprednisolone and a statement that
no adverse events were observed. Instead, it was as-
sumed that the risk for low-dose methylprednisolone
should lie between the risk for placebo and that for
high-dose methylprednisolone; therefore it was uni-
formly sampled from the intervals formed by the poster-
ior draws for those two alternatives.
Risk of serious adverse effects
The limited number of clinical trials performed for
methylprednisolone in MS relapses, in combination with
their small sample sizes, makes this source of evidence
insufficient to quantify the risks of serious adverse ef-
fects: for high-dose methylprednisolone, only two events
in total for all included serious adverse effects were re-
ported across the identified trials. Similarly, no published
observational studies on methylprednisolone or other
glucocorticoids in association with these adverse effects
could be used for risk quantification: these studies either
used different treatment definitions (e.g. with respect
to dose or duration), different outcome definitions, or
else they were not designed to estimate risk as per-
alternative probabilities, which is required in decision
analysis.
Instead a novel approach was used, in which upper
limits on true population risks are calculated as report-
ing ratios in collections of individual case reports [28].
Such risk limits were computed for the included seriousadverse effect-outcome combinations from within Vigi-
Base. The reporting ratio denominators included all
available reports, whether methylprednisolone was listed
as suspected (S), interacting (I), or concomitant (C). The
numerators included all S and I reports, while only those
C reports were included that did not contain informa-
tion implicating another drug. Also, for the numerators
a requirement was set that the time from drug initiation
to onset of the reaction should be at most 180 days. This
methodology is further detailed in Additional file 4, with
a proper account of the underlying assumptions.
To maintain a probabilistic analysis, different plausible
distributions were assigned the various risks over the in-
tervals from zero to their respective upper limits [28].
(For details, see Section ‘Sensitivity analyses’).
It should be noted that the method depicted here devi-
ates slightly from the illustration in Fig. 1: sampling is
for the probability of a serious adverse effect-outcome
combination directly, not separately for the effect and
the outcome. However, this difference is not influential
as the total probability for the adverse effect is simply
the sum of those for the various outcomes. The condi-
tional probability of a specific considered outcome is
then the fraction of the total probability contributed
from that particular outcome.
Because no limits could be computed for the no treat-
ment alternative, it was assumed that some proportion
of the risk from active treatment could be classified as
background risk that would apply to the no treatment
alternative as well. This background risk was calculated,
for each adverse effect-outcome combination, as the
average between the sampled values for low- and high-
dose methylprednisolone, respectively, multiplied by the
proportion. Different values were imputed for this un-
known proportion; see Section ‘Sensitivity analyses’.Estimation of utility variables
As illustrated in the fourth panel of Fig. 1, the sampled
probability values are combined with sampled utility
values in the expected utility calculations. Here, a tai-
lored approach was used to sample from the utility vari-
ables of the respective clinical outcomes [15, 29]. In this
approach, each utility is first assigned a standard uni-
form distribution, and qualitative relations are specified
that relate the desirability of the various clinical out-
comes to each other. Then, the totality of these relations
is used to shift the initial distributions accordingly. It is
also possible to specify minimum differences between
utility variables in case sufficient separation has not been
achieved. (For details, see Additional file 5). The main
benefit of this approach is that external data are not re-
quired; in particular, timely and costly elicitation studies
can be avoided.
Table 1 Serious adverse effects included into the benefit-risk assess
Adverse effect Included outcomes
Death










Ventricular arrhythmia/cardiac arrest Yes
Fig. 2 Probability distributions used over the derived risk intervals
for serious adverse effects. The uniform distribution puts equal belief
over the entire interval from zero to the upper limit, and so has an
expected value of half the upper limit. The truncated exponential
distributions, on the other hand, put increasingly more belief on low
risks. Their expected values are 0.19, 0.020 and 0.0020 times the upper
limit, respectively. Note that to benefit the clarity of the display, the
graphs for the two left-most exponential distributions have been
truncated: in reality they extend much higher for risks close to zero
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elling, blinded to any estimates of probability variables.
Because this benefit-risk assessment is made for the
whole patient population rather than a specific patient,
only logically implied or clinically well motivated rela-
tions were used. As recommended [15], a minimum util-
ity difference was included between non-lethal and
lethal outcomes, to reflect their intrinsically different
nature. Modelling was performed separately for patients
starting their relapse at EDSS 4 and EDSS 5, respectively,
to investigate whether relapse severity has any influence
on the overall benefit-risk profile.Sensitivity analyses
Four unknown components of the assessment were al-
tered in a series of sensitivity analysis scenarios. Two of
these components concern the risk of serious adverse
effects, and two concern the sampling from utility
variables.
As mentioned, different types of distributions over the
derived risk intervals for the serious adverse effects were
investigated; these are shown in Fig. 2. Further, the pro-
portion of the sampled risk values that is attributed to
the background, and that therefore determines the
values for the no treatment alternative, was varied
between 0 and 50 %.
The minimum utility difference between non-lethal
and lethal outcomes was altered over the range from 0
to 0.99. Also, as mentioned, different sets of qualitative
utility relations were used for patients at different levels
of relapse severity.
In addition, a set of auxiliary sensitivity analyses were
undertaken to determine the extent to which different
variables contributed to the overall uncertainty. This was
done by replacing all sampled values for a given variable
by the median of the sampled values for that variable.ment, listed alphabetically












Fig. 3 Decision tree model used for the benefit-risk assessment of methylprednisolone in MS relapses. Any sub-tree denoted with [+] is identical to the
sub-tree immediately above it
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lysis within each investigated scenario was based on
10,000 sampling iterations, yielding one preference rate
for each alternative. All sampled values for all probabil-
ity and utility variables in all scenarios, as well as the
resulting expected utilities and preference rates, are
freely available; for details, see ‘Availability of supporting
data’.Results
Included serious adverse effects
A total of eleven serious adverse effects were included,
as shown in Table 1; hence there was a considerable
overlap among the ten adverse effects chosen from the
two dose groups. The respective definitions of these
adverse effects are given in Additional file 6. In total,
26 serious adverse effect-outcome combinations were
sufficiently often reported to be considered in the
study.
With the exception of hepatotoxicity, all of the included
adverse effects are labelled for methylprednisolone [30].
However, an association between high-dose methylpred-
nisolone and hepatotoxicity has recently been reported,
with strong support for a causal link [5, 6]. At the same






Durelli 1986a [31] 7035 mgb IV 15 days
Milligan 1987 [32] 2500 mg IV 5 days
La Mantia 1994 [27] 5750 mg IV 14 days
Barnes 1997 [33] 3000 mg IV 3 days
Sellebjerg 1998 [34] 3676 mg PO 15 days
Visser 2004 [35] 2500 mgc IV 5 days
Ramo-Tello 2013 [36] 3000 mg IV 3 days
Ramo-Tello 2013 [36] 3750 mg PO 3 days
Low-dose
methylprednisolone
Milanese 1989 [26] 390 mg IV 14 days
La Mantia 1994 [27] 390 mg IV 14 days
Barnes 1997 [33] 588 mg PO 21 days
Placebo Miller 1961 [37] - IM 21 days
Rose 1970 [38] - IM 14 days
Durelli 1986a [31] - IV 15 days
Milligan 1987 [32] - IV 5 days
Sellebjerg 1998 [34] - PO 15 days
IV intravenous, PO per oral, IM intramuscular
a Only the 15 days controlled period of this trial is considered here
b Based on a weight of 70 kg
c Patients also received 2 % human albumin
d This study lacked reported assessments in the 14–28 day interval
e No EDSS measurement performed; the result refers to the fraction with an ‘undou
f Conversion based on the assumption that a DSS of e.g. 4 is equally likely to corresdiscussed adverse effects of glucocorticoids, such as skin
reactions, eye reactions and infections [3, 4].Structural model
The decision tree used for the evaluation is depicted in
Fig. 3. In total there are 56 clinical outcomes considered
for the three alternatives.Effectiveness
The study arms included for the estimation of effectiveness
are reported in Table 2. (For details concerning the article
selection process, see Additional file 7). There are eight,
three and five arms included for high-dose methylpredniso-
lone, low-dose methylprednisolone and placebo, respect-
ively. These include in total 152, 62 and 156 patients,
respectively, from ten different studies [26, 27, 31–38]. The
included patients’ EDSS scores at start of treatment are
centred between 4.0 and 5.0 for a majority of studies.
The estimated distributions for effectiveness, i.e. the
probability of having a reduced relapse, are displayed in
Fig. 4. Although the distributions are wide, the ordering
of the alternatives is the one that would be pharmaco-
logically expected, and the one depicted from the crude








15 10/11 5.8 (mean) Poser 1983 [51]
28 10/13 4.0 (median) McDonald 1977 [52]
14 8/10 4.6 (mean) McDonald 1977 [52]
28 13/38 6.0 (median) Not stated
21 14/26 4.5 (median) Poser 1983 [51]
28 6/9 3.5 (median) Not stated
28 15/23 4.0 (median) McDonald 2005 [53]
28 15/22 3.0 (median) McDonald 2005 [53]
30d 3/10 4.9 (mean) McDonald 1977 [52]
14 6/10 4.7 (mean) McDonald 1977 [52]
28 20/42 5.0 (median) Not stated
21 4/18e Not stated Not stated
28 39.25/94f 5.2 (mean) Rose 1968 [54]
15 4/10 5.9 (mean) Poser 1983 [51]
28 2/9 4.0 (median) McDonald 1977 [52]
21 6/25 4.0 (median) Poser 1983 [51]
bted response to treatment’
pond to EDSS 4.0 as EDSS 4.5
Fig. 4 Estimated effectiveness for the three alternatives. The posterior
median values were 0.64, 0.47 and 0.34 for high-dose methylprednisolone,
low-dose methylprednisolone and placebo, respectively
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Table 3 lists the study arms included for the estimation of
the risk of non-serious adverse effects, taken from ten dif-
ferent studies [27, 31, 34, 36, 38–43]. (For a detailed flow
of the article selection process, see Additional file 7). For
high-dose methylprednisolone there are eleven arms in-
cluding a total of 301 patients, and for placebo there are
three arms with 129 patients in total. For both treatments
there is clearly great heterogeneity across the different
studies.
The estimated distributions are displayed in Fig. 5.
The distributions are again very wide, and again the ex-
pected order is seen. However, here it has been obtained
by design since the risk for low-dose methylprednisolone
was assumed to lie between the risks for placebo and
high-dose methylprednisolone.
Risk of serious adverse effects
The computed upper risk limits are displayed in Table 4.
The aggregate numbers are high, which indicates that
the limits are conservative. One possible explanation is
the high threshold used for seriousness, which affects
the safety margins of these limits [28]. As mentioned, for
high-dose methylprednisolone only two events were re-
ported across all investigated clinical trials. Since these
studies comprise over 300 patients, even half of the
computed limits are likely to be very conservative. This
supports the choice in the sensitivity analysis of using
uniform distributions as the most pessimistic scenario
with respect to these risks.
Utility modelling
The utility modelling was carried out in several steps.
To reduce the complexity slightly, the serious adverse
effect-outcome combinations were grouped at common
levels of utility. For example, all clinical outcomes con-
sisting of a reduced relapse and a life-threatening serious
adverse effect were given the same utility. This is
because they are all similar in a qualitative sense, much
like the non-serious adverse effects are. Among the per-
sistent effects, osteonecrosis and diabetes were deemed
least undesirable, as they are most likely not related to
any life-threatening triggering event, and as they are
generally manageable. At the other end of the spectrum,
persistent periods of cardio-pulmonary distress, ven-
tricular arrhythmias and seizures are likely to have been
started with a life-threatening event, and should be very
unpleasant and difficult to manage. Perhaps controver-
sially, the lethal outcomes were divided into two groups,
where death by pancreatitis, cardio-pulmonary distress,
or gastrointestinal haemorrhage could be expected to be
extended in time and very painful. In contrast, a lethal
anaphylaxis or cardiac arrest should be quick with little
suffering.The complete results of the modelling are displayed in
Fig. 6. Relations in the vertical direction are clear given
the groupings just described. Relations in the horizontal
direction are equally clear since the clinical outcomes
are identical in terms of adverse effects but differ with
respect to the beneficial effect. There are two diagonal
arrows that apply regardless of the patient’s relapse
severity, where one signifies the quite clear separation
between non-lethal and lethal clinical outcomes, which
is even assigned a minimum utility difference. The other
implies that it is preferable to have a reduced relapse
with a non-serious adverse event compared to having a
standard relapse and no adverse event. This should be
quite clear, considering what an improvement from
EDSS 4 to EDSS 3 means: one has no impairments to
walking compared to just being able to walk about
500 m without aid or rest. It should also be borne in
mind that whereas the non-serious adverse effects are
transient, the lower intensity of the MS induced by the
improvement is a benefit that lasts until the end of the
relapse, i.e. up to 6 months. At the same time, the differ-
ence between EDSS 4 and EDSS 3 is not immense; for
example, at EDSS 4 one is still able to be ‘up and about’
Table 3 Details of included study arms for the estimation of risk for non-serious adverse effects
Intervention Study Cumulative
dose
Route Duration Follow-up Fraction with at least
one adverse event
High-dose methylprednisolone Abbruzzese 1983 [39] 8400 mga IV 15 days Not stated 3/30b
Durelli 1986c [31] 7035 mga IV 15 days 15 days 9.2/13d
Thompson 1989 [40] 3000 mg IV 3 days 84 days 1/29
Sellebjerg 1998 [34] 3676 mg PO 15 days 56 days 23/26
La Mantia 1994 [27] 5750 mg IV 14 days 14 days 0/10
Soelberg-Sorensen 2004 [41] 3000 mge IV 3 days 182 days 30/40f
Martinelli 2009 [42] 5000 mg IV 5 days 28 days 11/20
Martinelli 2009 [42] 5000 mg PO 5 days 28 days 15/20
Ramo-Tello 2013 [36] 3000 mg IV 3 days 28 days 24/24
Ramo-Tello 2013 [36] 3750 mg PO 3 days 28 days 24/25
Shaygannejad 2013 [43] 3000-5000 mg + taper IV 13–20 days 90 days 58/64
Placebo Rose 1970 [38] - IM 14 days 28 days 8/94b
Durelli 1986c [31] - IV 15 days 15 days 5.0/10d
Sellebjerg 1998 [34] - PO 15 days 56 days 8/25
IV intravenous, PO per oral, IM intramuscular
a Based on a weight of 70 kg
b Patients were given antacids
c Only the 15 days controlled period of this trial is considered here
d Counts were reported per adverse event term; the number displayed here is based on an independence assumption
e Patients also received 0.1 % human albumin
f Includes multiple sclerosis as an adverse event
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preferable to be at that level, even with a non-serious ad-
verse event added, compared to being at EDSS 3 and
experiencing a life-threatening adverse event. Similarly,
it should be preferable to be at EDSS 4 and have persist-
ent osteonecrosis or diabetes added, compared to being
at EDSS 3 and having persistent cardio-pulmonary dis-
tress or any equivalent disability added.
At EDSS 5, one is impaired to the level that one cannot
work a full day, and one can walk only about 200 m with-
out aid or rest. It was deemed reasonable that patients
would prefer to remain at that level, even with a non-
serious adverse event added, rather than having the reduc-
tion down to EDSS 4 and a persistent disability from the
intermediate group. This group contains e.g. psychosis,
which should be quite a terrifying state to endure for an
extended period of time.
Clearly these latter diagonal relations are very diffi-
cult to decide upon in a general sense, and these ex-
istential choices made here should be seen primarily
as rough guidance, though they were made by a very
experienced physician who has encountered patients
with all of these different medical problems. This
framework for benefit-risk assessment could be used
for the treatment of an individual patient, in which
case the specific preferences of that patient should be
used instead.
The resulting distributions guided by these qualitative
relations are shown in Fig. 7. They appear to conveyreasonably well the intents of the utility modelling. It
should be noted that lack of benefit (i.e. ‘standard
relapse’) in combination with no or only non-serious
adverse effects has a notably lower utility if the relapse
starts at EDSS 5 than if it starts at EDSS 4. This is clinic-
ally sensible, and should imply that treatment effective-
ness is more rewarded for more severe relapses.
Evaluation results
As indicated in Fig. 1, once the structure of the
model has been specified, and once distributions are
available for all constituent probability and utility var-
iables, it is possible to compute expected utilities for
the considered alternatives over the iterations of the
probabilistic analysis. Figure 8 shows how the result-
ing expected utility of the respective alternatives was
distributed in one specific sensitivity analysis scenario.
While the graphs superficially suggest very small differ-
ences between the alternatives, Fig. 8 fails to recognise the
many inter-dependencies that exist between variables of
this assessment. These dependencies imply that proper in-
ference requires comparisons to be made at the iteration
level prior to aggregating the results. Specifically, Fig. 9 is
based on the differences in expected utility obtained over
the 10,000 iterations. This figure illustrates the concept of
the preference rate and shows much clearer than Fig. 8
the comparative results for the alternatives.
The main finding in the evaluation results across all
considered sensitivity analysis scenarios is the inferiority
Fig. 5 Estimated risk of non-serious adverse effects for the three
alternatives. The distribution for low-dose methylprednisolone has
not been estimated from data, but was obtained by random sampling
of values between those sampled for placebo and high-dose
methylprednisolone. The posterior median values were 0.56, 0.45
and 0.32 for high-dose methylprednisolone, low-dose methylprednisolone
and placebo, respectively
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alternative in less than 5 % of all scenarios, and in no
single scenario was its preference rate above 50 %. This
finding is visually evident in Fig. 10, which displays the
results based on the utility modelling for less severe
relapses starting at EDSS 4. Essentially, high-dose meth-
ylprednisolone and the no treatment alternative alternate
as the option with the highest preference rate, depending
on the setting of the sensitivity analysis variables. As the
distributions over the risk intervals for serious adverse
effects become more and more skewed towards lower
risks (cf. Fig. 2), the more preferable high-dose methyl-
prednisolone becomes: this is evident by comparing the
panel rows from left to right. In contrast, as the mini-
mum utility difference between non-lethal and lethal
outcomes is increased, the preference rate of high-dose
methylprednisolone decreases substantially: this effect is
visible in every panel of the display. The reason is that
as this minimum difference increases, so does thepenalty incurred by the active treatment alternatives for
their higher risk of lethal outcomes. The least impacting
of the considered sensitivity analysis variables was the
proportion of risk attributed to the background for
serious adverse effects: results change only modestly
over the various panel rows.
The minimum utility difference is in itself quite opaque.
However, some aid to its interpretation is possible by spe-
cifying three clinical outcomes and translating the utility
difference into a gamble including those outcomes [15].
Specifically, from the sampled utility values one can deter-
mine at what point the typical patient becomes indifferent
between the status quo outcome (a standard relapse with-
out adverse effects) and gambling between the best pos-
sible outcome (a reduced relapse without adverse effects)
and the worst possible outcome (lethal pancreatitis or any
of its equivalents in Fig. 6). For example, in Fig. 10 a mini-
mum utility difference of 0.5 corresponds to indifference
between status quo and gambling with a probability for
the lethal outcome of about 7 %, and therefore a probabil-
ity of about 93 % for the best possible outcome. At a mini-
mum utility difference of 0.9, the typical patient is more
risk-averse and requires the probability of the lethal out-
come to go down to about 1 % before considering the
gamble equivalent to the status quo outcome.
Figure 11 displays the same types of results as Fig. 10,
though based on the utility modelling for more severe
relapses starting at EDSS 5. Whereas the overall conclu-
sions are the same, the results show that when everything
else is kept constant, high-dose methylprednisolone is
more likely to be the preferred alternative when the re-
lapse is severe. This makes sense clinically and fits with
the observations from the utility distributions in Fig. 7.
(See Section ‘Utility modelling’).
One observation is that high-dose methylprednisolone
never reaches a preference rate above 75 % in any of the
investigated scenarios, which suggests that some aspect of
the assessment contains too much uncertainty to clearly
recommend high-dose methylprednisolone. In Fig. 12 it is
demonstrated that the removal of sampling uncertainty
from all utility variables has only a modest effect on the
maximum preference rate. However, the removal of un-
certainty from probability variables has a much more pro-
found effect. In particular, high-dose methylprednisolone
does reach a 100 % preference rate when the risks for ser-
ious adverse effects are kept at a fixed minimal level, as
seen in the bottom panel row in Fig. 12. This result is co-
herent with the wide distributions for probability variables
presented in Figs. 4 and 5.
Discussion
This is the first ever assessment of methylprednisolone
in MS relapses that considers both the effectiveness of
treatment and its risk for adverse effects. Our results
Table 4 Upper risk limits computed for the various combinations of serious adverse effects and outcomes
Adverse effect Outcome Upper risk limit (%)
Low-dose methylprednisolone High-dose methylprednisolone
Acute severe allergy Lethal 0.24 0.00a
Life-threatening 2.65 1.18
Cardio-pulmonary distress Lethal 0.33 0.79
Persistent 0.02 0.39
Life-threatening 0.86 1.71
Diabetes Lethal 0.02 0.53
Persistent 0.86 1.05
Life-threatening 0.07 0.13
Gastrointestinal haemorrhage Lethal 0.26 0.39
Persistent 0.13 0.13
Life-threatening 0.37 0.79
Hepatotoxicity Lethal 0.11 0.13
Persistent 0.11 0.53
Life-threatening 0.29 0.66
Myopathy Persistent 0.46 0.79
Life-threatening 0.07 0.13
Osteonecrosisb Persistent 0.57 1.58
Pancreatitis Lethal 0.04 0.13
Psychosis Persistent 0.04 0.13
Life-threatening 0.07 0.13
Seizure Lethal 0.09 0.39
Persistent 0.13 0.00a
Life-threatening 0.13 0.13
Ventricular arrhythmia/cardiac arrest Lethal 0.55 1.05
Persistent 0.09 0.13
Life-threatening 0.86 1.18
Totalc Lethal 1.65 3.42
Persistent 2.43 4.73
Life-threatening 5.36 6.04
a This clearly is not an upper limit; therefore, in the analyses the corresponding limits for low-dose methylprednisolone are used
b No requirement on the reported time to onset, due to the difficulties in diagnosing osteonecrosis
c The grand total for all three outcomes is 9.44 and 14.19 % for low-dose and high-dose methylprednisolone, respectively, based on a plain summation conforming to
the structure of the model, where the effects are considered to be mutually exclusive. If one instead assumes that they are independent, the total risks of experiencing
any of the effects are 9.07 and 13.34 %, respectively
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men of methylprednisolone over one with doses
below 1000 mg. Although there is a paucity of data,
especially for the low-dose alternative, our results are
reassuring with respect to current treatment recom-
mendations and clinical practice.
The subsequent discussion addresses, in turn, study
design choices, methodological issues and related work.
Study design choices
This assessment considers a single active treatment, given
at two different doses. Corticotropin was not included, asit has been essentially abandoned due to its impractical
administration. Dexamethasone has been studied only to a
limited extent [26, 27], and there was too little data for it
to be considered here. The same applies for plasma ex-
change, which has been proposed as possible second-line
treatment [1]. Intravenous immunoglobulin does not ap-
pear to be effective in MS relapses [1].
Our definitions of high- and low-dose methylpredniso-
lone are by necessity arbitrary, given that no generally
accepted definitions exist. While the dose that strikes
the optimum balance between benefit and risk may not
conform to either of these definitions, they do have the
Fig. 6 (See legend on next page.)
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Fig. 6 Results from the qualitative utility modelling. In the figure, grey boxes indicate clinical outcomes that include a standard relapse, i.e. no
benefit, whereas white boxes signify a reduced relapse. The arrows point from a less desirable to more desirable clinical outcome. The two dashed
arrows apply for patients starting their relapse at EDSS 4, and the dotted arrow for patients starting at EDSS 5. The zigzag line indicates a minimum
utility difference between non-lethal and lethal outcomes
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which facilitates assessment. Also, it appears that few
studies to date have been concerned with doses in the
intermediate dose range excluded from consideration
here. Finally we note that existing treatment recommen-
dations agree with our adopted definition of high-dose
methylprednisolone [1], and that the resulting dose clas-
sifications in previous analyses conform with ours [2].
In previous appraisals of glucocorticoids for MS re-
lapse management, there has been a strong emphasis on
route of administration [9, 10]. Pharmacologically, the
bioavailable dose should be far more important than the
route of administration, for which reason it is surprising
that the oral bioavailability of methylprednisolone has
not been ascertained. Only one study compared the bio-
availability of oral prednisone and intravenous methyl-
prednisolone at equivalent doses, and could not
demonstrate any difference after 48 h [44]. The lowest
per-oral dose from any study considered as high-dose
methylprednisolone in this assessment was 3676 mg.
Hence, this dose would qualify as high according to our
definition so long as the bioavailability could be assumed
to be 55 % or higher. Although the quoted study [44] in-
cluded only 16 patients and used a chemically similar
but not identical glucocorticoid, this assumption seems
very reasonable. Nevertheless, our assessment frame-
work is transparent and flexible enough that a re-
assessment based on route of administration rather than
dose would be easily possible.
In this analysis, estimation of effectiveness relies on
EDSS values assessed sometime between 14 and 28 days
from start of treatment. Our target time point of 28 days
could possibly be too early to capture the full extent of
the treatment effects. However, this design choice is ad-
vantageous for the power of the analysis, since it allows
inclusion of studies that lack long-term follow-up. Also,
across different studies, the consistency in the actual as-
sessment time points would likely decrease with a later
target time point. On the whole, 28 days appears to be a
reasonable choice, although it too could be altered
within the employed assessment framework.
Exclusion of optic neuritis
The biological link between MS and optic neuritis is un-
questionable [45], even though clinically isolated optic
neuritis is neither a sufficient nor a necessary condition
for the diagnosis of MS [46]. Solid arguments can be
made for any of the following plausible alternativedesigns: analysing MS relapse patients only, analysing
MS relapse and acute optic neuritis patients in parallel,
or analysing both groups jointly. As with the other de-
sign choices discussed above, our framework could ac-
commodate either alternative, if the appropriate data is
provided.
The alternative comprising parallel, but separate, as-
sessments with the same overall methodology would be
an appealing complementary study: an interesting idea
for further research.
As regards the alternative of conducting a joint as-
sessment, such a design would have benefitted the
power of our analysis. However, it also would have
created two rather severe analytical obstacles. First,
major clinical trials of glucocorticoids in acute optic
neuritis include only a very limited number of pa-
tients diagnosed with MS [47, 48], thus introducing
an important source of heterogeneity and potential
bias. A clear majority of patients, even among those
on placebo, improve their EDSS quickly [48], which
supports the notion that these patients are in an earl-
ier phase of their clinical course and therefore quali-
tatively different compared to the patients included in
MS relapse trials.
Secondly, as far as we are aware there is only a single
acute optic neuritis trial that reports outcomes in terms
of EDSS improvement [48]. The others report only vis-
ual outcomes, which are non-trivial to translate into
equivalents of EDSS improvement, both conceptually
but also practically as the translation would require
patient-level data.
Methodological issues
The literature search strategy in this assessment is
slightly unorthodox: it considers studies that have been
included in earlier systematic reviews of glucocorticoids
in MS, or that have referred to any such review. Our
coverage up to November 2009 is at least as good as that
of a dedicated European Federation of Neurological
Societies task force, which scanned the literature at that
point in time [22]. Studies published later than that
would be missed if they did not refer to any of the seven
reviews considered here [1, 2, 8–10, 21, 22], and were
not investigated in the 2012 Cochrane review by Burton
et al. [9]. This risk should be small.
When estimating effectiveness and risk of non-serious
adverse effects, any study was included that contained at
least one arm corresponding to any of the considered
Fig. 7 (See legend on next page.)
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Fig. 7 Sampled utility values for a subset of clinical outcomes. The display includes one clinical outcome from each group in Fig. 6. Clinical
outcomes are divided into two panel columns according to whether or not they entail the considered beneficial effect. Also, results are shown
separately by panel row according to relapse severity as measured by initial EDSS. (Cf. the different relations indicated in Fig. 6 for patients starting
their relapses at EDSS 4 and 5, respectively.) Here, the minimum utility difference between non-lethal and lethal outcomes has been set to 0.25
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meta-analysis strategy, where only such studies are
included that contain all treatments of interest. A prag-
matic motivation for our approach is that no single study
was identified that compared both low- and high-dose
methylprednisolone to placebo. Likewise, a head-to-head
comparison of only high- and low-dose methylprednisolone
was not feasible since the risk for non-serious adverse ef-
fects was not directly estimable from data for the low-dose
alternative. Apart from these pragmatic considerations, itFig. 8 Resulting expected utility distributions in one specific sensitivity
analysis scenario. These distributions of expected utilities were obtained
for the three considered alternatives in the following scenario: over
the derived risk intervals for serious adverse effects the truncated
Exponential (5/upper limit) distribution was applied; the proportion
of risk attributed to the background for serious adverse effects
was set to 10 %; the minimum utility difference between non-lethal
and lethal outcomes was 0.4; and the utility modelling was for
patients starting their relapse at EDSS 4. The median values of
the resulting expected utilities were 0.91, 0.90 and 0.90 for high-dose
methylprednisolone, low-dose methylprednisolone and the no
treatment alternative, respectivelyshould be noted that since decision analysis uses per-
alternative probabilities, there is no intrinsic require-
ment on included studies to contain all treatment alter-
natives. On the contrary it can be argued that omitting
a study that misses one or more alternatives would be a
waste of information concerning the alternatives that
are in fact included in that study: after all, studies were
required to fulfil certain pre-defined inclusion criteria,
which should provide a baseline level of homogeneity
across all studies.
The overall framework in this benefit-risk assessment
is decision analysis, which has been recommended else-
where [12]. The use of probabilistic evaluation is man-
dated by one of the leading bodies for health technology
assessment globally [49]. Within this framework, two
novel methods are used in this assessment: one for util-
ity modelling [15], and one for deriving limits on the risk
of serious adverse effects [28]. The former method has
certain advantages: it is relatively quick; it requires nei-
ther utility elicitation studies nor collection of external
utility estimates; and it avoids many of the assumptions
inherent to time-aggregating utility metrics like the
quality-adjusted life year [15]. At the same time, qualita-
tive relations can only carry so much information, and
typically minimum utility differences must be used. This
requires additional sensitivity analysis scenarios, which
may make interpretation more difficult.
The use of risk limits computed from individual case
reports was required since no suitable risk estimates
were publicly available. These limits are valid only under
certain assumptions, which are likely to be fulfilled here
(see Additional file 4). Because the overall evaluation re-
sults were highly sensitive to the distribution of risks up
to their respective limits, it would be worthwhile to in-
vestigate whether more precise risk estimates could be
obtained from another source. One candidate would be
a large, possibly multi-national, repository of longitu-
dinal patient records.Limitations
This assessment has several limitations, of which
most can be attributed to a paucity of data in general,
and a complete absence of appropriate data in spe-
cific aspects.
Clinical trials measure efficacy, which seldom corre-
sponds precisely to effectiveness seen in real-world clin-
ical use. Hence, in this assessment effectiveness is likely
Fig. 9 Resulting preference rates in one specific sensitivity analysis scenario. These histograms are based on the same results as those presented
in Fig. 8. In each panel, the difference in expected utility was computed between the alternative indicated above the panel and the maximum
expected utility for the other two alternatives. Using the left panel as an example, in each of the 10,000 iterations a difference was computed
between the sampled expected utility for high-dose methylprednisolone and the highest expected utility of those sampled for low-dose
methylprednisolone and the no treatment alternative. The 10,000 values for the difference thus obtained were then used to construct the displayed
histogram. This means that the proportion of this histogram that is to the right of zero, i.e. the coloured proportion, is the fraction of all iterations in
which high-dose methylprednisolone had the highest expected utility. Hence, this is precisely the preference rate for high-dose methylprednisolone,
in this specific sensitivity analysis scenario. (See Fig. 1 for a definition of the preference rate.) Here, the preference rates are 45, 25 and 30 % for high-
dose methylprednisolone, low-dose methylprednisolone and the no treatment alternative, respectively
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ably so. Clinical trial patients on placebo are probably
more unlike patients in clinical practice who abstain
from treatment than are clinical trial patients on active
treatment in relation to their clinical practice counter-
parts. Publication bias, if present, will most likely select-
ively overestimate the effectiveness of active treatment.
The risk of non-serious adverse effects from low-
dose methylprednisolone could not be estimated from
data. Instead, risk values were sampled uniformly
from the intervals formed by the values sampled for
the other two alternatives. The resulting average
placement of low-dose methylprednisolone at equal
distance from placebo and high-dose methylpredniso-
lone is likely to underestimate its true risk: the doses
classified as low here are not low in an absolute
sense, and are certainly high enough to induce non-
serious adverse effects typical for glucocorticoids, e.g.
insomnia and oedema.
The available data did not permit probability vari-
ables, in particular effectiveness, to be estimated sep-
arately for patients with differentially severe relapses.
This would have been highly desirable given that such
differentiation was used in the utility modelling.
Further, potentially important covariates such as age,
gender, concomitant medication and pre-relapse disability
could not be taken into account since patient-level data
from the included studies were not provided, even after
request.Benefit was in this assessment defined as an im-
provement of at least one point on the EDSS. While
this definition has the advantage of being commonly
used and thus avoids unnecessary exclusion of poten-
tial studies, it also has certain limitations. First, it is
contingent on the EDSS itself. This implies that only
clinical assessment of patient disability is considered,
while other aspects reflected by e.g. quantitative tests
of neurological performance or patient-reported out-
comes are disregarded [50]. Secondly, there is no dif-
ferentiation with respect to the degree of recovery.
This would have required patient-level data; however,
even if such data had been accessible, the ordinal na-
ture of the EDSS would have severely complicated the
analysis of variable degrees of recovery.
A limitation with all included analyses based on the in-
dividual case reports in VigiBase is that they represent
patients with mixed indications. A restriction to MS
patients only was not feasible since the indication was
very often not stated in the reports, which would have
caused too severe a loss of data on harms.
Related work
Although there is no prior benefit-risk assessment of
methylprednisolone in MS relapses, the meta-analysis by
Miller et al. [2] is highly relevant in relation to our re-
sults for the respective alternatives’ effectiveness.
Miller et al. conclude that high-dose methylpredniso-
lone is more effective than placebo but equally
Fig. 10 Evaluation results based on the utility modelling for patients starting at EDSS 4. Within each panel, the alternatives’ preference rates are
shown at varying levels of the minimum utility difference. Distributions over the risk intervals for serious adverse effects are varied column-wise,
with risks generally decreasing to the right (see main text). The proportion of risk attributed to the background for serious adverse effects is
increased by row downwards. As an example, the preference rates presented in Fig. 9 are found in the second row and the second column, at
the minimum utility difference 0.4
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this assessment the high-dose regimen is clearly more
effective than its low-dose comparator, as seen in
Fig. 4.
Two possible explanations have been identified that
could explain this discrepancy. Miller et al. use as their
endpoint the mean change in EDSS rather than thefraction of improved patients; and they include only
two studies, namely those where high- and low-dose
methylprednisolone are compared head to head (cf. the
discussion under ‘Methodological issues’). The latter
discrepancy is likely to be the most important, given
the results obtained by Barnes et al. [33], which con-
tributed 80 % of all patients in the analysis by Miller
Fig. 11 Evaluation results based on the utility modelling for patients starting at EDSS 5. This display is analogous to that in Fig. 10, albeit based
on a scenario that considers more severe relapses
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lone had an effectiveness of 0.34 in the study by Barnes
et al., which is a value that deviates considerably from
the seven other high-dose arms considered: none of
those had a value below 0.5, and the posterior median
value from all eight study arms combined was 0.64. At
the same time, the value for low-dose methylpredniso-
lone in that same study was 0.48, which is very close to
the overall estimated effectiveness for that alternative.Hence, it seems that Miller et al. have grossly underes-
timated the effectiveness of high-dose methylpredniso-
lone by including only studies where it was compared
head to head with low-dose methylprednisolone, which
led to selecting a highly unrepresentative study as the
main contributor to their pooled results. Our results in
Fig. 4 correspond to a dose–response relationship that is
pharmacologically plausible. Also, it seems that our results
comply with experience from clinical practice: if the low-
Fig. 12 Evaluation with respect to various sources’ contribution to overall uncertainty. This display, like the one in Fig. 10, is based on the utility
modelling for patients starting at EDSS 4. The background risk proportion for serious adverse effects is kept constant at zero, which means that
the left column here is identical to the top row in Fig. 10. This reference is compared to two sets of analyses: the removal of all sampling
uncertainty from probability variables and utility variables, respectively, in the middle and right columns. This fixation effect was achieved by
replacing all sampled values of a particular variable by the median of the sampled values for that variable
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would probably have been used more often, as it could be
expected to be favourable on the risk side.
Conclusions
Over the numerous sensitivity analysis scenarios consid-
ered in this quantitative benefit-risk assessment of meth-
ylprednisolone in MS relapses, the low-dose regimen of
less than 1000 mg over at most 31 days was rarely the
preferred alternative. And when it was, the level of
confidence in its status as most preferred was not great.
Hence, based on the available information, a change of
treatment recommendation from high- to low-dose
methylprednisolone in this indication cannot be justified.
However, it must be borne in mind that the risk of non-
serious adverse effects was not evaluable from data for
low-dose methylprednisolone, and its effectiveness was
estimated based on only three trials comprising merely
62 patients in total.
Overall, our results were not able to differentiate
between the high-dose methylprednisolone regimen of
at least 2000 mg over at most 31 days and the no treat-
ment alternative. The more skewed towards zero the risk
distributions for serious adverse effects, and the less
risk-averse the patient population, the more favourable
were the results for high-dose methylprednisolone. How-
ever, the considerable posterior uncertainty in the estimates
of effectiveness and risk of non-serious adverse effects de-
nied high-dose methylprednisolone a higher preference rate
than 75 % in any sensitivity analysis scenario. All of this, in
addition to the severe paucity of data for low-dose methyl-
prednisolone discussed above, suggests that more clinical
research is needed. Any clinical neurologists should feel
compelled to assist in this process to optimise the treatment
of MS using corticosteroids, e.g. by contributing patients to
clinical trials, submitting well-documented case reports of
suspected adverse reactions, or carefully managing patients’
health records to make them as useful as possible for
research purposes.
Our results clearly indicate that methylprednisolone
treatment is more likely to be the right decision in severe
MS relapses, which makes sense from a clinical point of
view. This finding also highlights sensitivity in the overall
results to the particular relations used in the utility model-
ling. An important implication is that for an individual pa-
tient, this assessment can serve merely as a starting point
to guide treatment, and his or her specific preferences
should be carefully considered in the decision.
The overall superiority of high-dose methylpredniso-
lone relative to its low-dose comparator was seen in
spite of additional risks with higher doses, e.g. for
hepatotoxicity [6]. However, we wish to emphasise the
importance of considering such small but possibly
significant risks in the management of individualpatients: if the adverse effect does set in, it must be
recognised and managed, and alternative treatments
must be considered.
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